ATI-1501 is Appili's liquid oral reformulation of the antibiotic metronidazole, which has been licensed to Saptalis. The FDA established a Prescription Drug User Fee action date of September 23, 2023.
Metronidazole is a widely used frontline oral treatment with over 10 m prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections.
The current tablet form of metronidazole is the only approved oral form on the US market and its bitter taste and lack of appropriate dosage forms prove highly difficult for patients with trouble swallowing, presenting frequent treatment compliance challenges.
Approval of ATI-1501 will unlock the potential to achieve relief and recovery for the millions facing these devastating infections by offering a convenient treatment option.
ATI-1501 is a proprietary taste-masked liquid suspension reformulation of metronidazole. Metronidazole is a widely used front-line oral treatment with over 10m prescriptions written in the United States every year and is used to treat parasitic and anaerobic bacterial infections, which heavily burden elderly patients.
The bitter taste of metronidazole and lack of appropriate dosage forms for patients with difficulty swallowing presents treatment compliance challenges, which ultimately can lead to detrimental effects on patient outcomes, healthcare costs, infection control, and antibiotic resistance.
ATI-1501 is designed to enable broader use of metronidazole and provide a solution with the same safety and efficacy profile provided by metronidazole for 50 years, that is both easy to swallow and good tasting, thereby helping patients to adhere with their medication and improve their prognoses.
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.
By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.
The company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections.
Led by a proven management team, Appili is at the epicenter of the global fight against infection.
Saptalis Pharmaceuticals is a pharmaceutical company specialized in development, manufacturing, and commercialization of generic and innovative products in liquid and semi-solid dosage forms.
Located in the Hauppauge Industrial Park on Long Island, NY, USA, Saptalis has fully equipped Research & Development Laboratories and state of the art commercial scale manufacturing facility designed to meet FDA cGMP requirements.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling